Cargando…

Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review)

Programmed death ligand 1 (PD-L1) is widely expressed in human tumors. It is widely known for its immunosuppressive function as it can help tumor cells evade T cell immune killing through the PD-1/PD-L1 signal. A number of clinical trials have proved that the destruction of the combination of PD-1 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Jiao, Jiang, Wei, Liu, Liang, Zhan, Wenli, Wu, Yudi, Xu, Xiangshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713762/ https://www.ncbi.nlm.nih.gov/pubmed/36466997 http://dx.doi.org/10.3892/ol.2022.13596

Ejemplares similares

Long non-coding RNA signature in colorectal cancer: research progression and clinical application
por: Wu, Yudi, et al.
Publicado: (2023)

Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors
por: Nihira, Naoe Taira, et al.
Publicado: (2022)

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
por: Dong, Peixin, et al.
Publicado: (2018)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

New insights into the important roles of tumor cell-intrinsic PD-1
por: Zheng, Hongmei, et al.
Publicado: (2021)

Potential therapeutic targets for sarcopenia identified by Mendelian randomisation
por: Jiang, Wei, et al.
Publicado: (2023)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
por: Laubach, Kyra, et al.
Publicado: (2023)

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
por: Filippone, A., et al.
Publicado: (2022)

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
por: Gupta, Harshita B, et al.
Publicado: (2016)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma
por: Zhao, Yue, et al.
Publicado: (2022)

Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma
por: Cui, Peng, et al.
Publicado: (2020)

CT-determined sarcopenia is associated with neutropenia in patients undergoing hyperthermic intraperitoneal chemotherapy for gastrointestinal cancer
por: Jiang, Wei, et al.
Publicado: (2023)

PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer
por: Chen, Chunhua, et al.
Publicado: (2021)

The role of exosomal PD-L1 in tumor progression and immunotherapy
por: Xie, Feiting, et al.
Publicado: (2019)

PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma
por: Lu, Li-Gong, et al.
Publicado: (2022)

Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment
por: Jin, Ying, et al.
Publicado: (2022)

Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma
por: Zhang, Yuting, et al.
Publicado: (2021)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer
por: Ma, Yunxia, et al.
Publicado: (2022)

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
por: Li, Hui, et al.
Publicado: (2020)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study
por: Yuan, Wenli, et al.
Publicado: (2021)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
por: Wang, Luyao, et al.
Publicado: (2023)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
por: Zaslavsky, Alexander B., et al.
Publicado: (2020)

Tumor-derived small extracellular vesicles promote breast cancer progression by upregulating PD-L1 expression in macrophages
por: Xu, Di, et al.
Publicado: (2023)

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
por: Chao, Yi-Chun, et al.
Publicado: (2021)

Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
por: Long, Yiru, et al.
Publicado: (2023)

Mechanisms regulating PD-L1 expression on tumor and immune cells
por: Chen, Shuming, et al.
Publicado: (2019)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ncfnpmh26ukje0dft4oo2p1hc1